TB & Outbreaks Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB & Outbreaks Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Aspergillosis
Data on aspergillosis discussed by researchers at University of Houston
June 3rd, 2008
"The safety and concentration-dependent pharmacodynamic characteristics of the echinocandins make them ideal candidates for dosage escalation in the treatment of aspergillosis. However, paradoxical attenuation of antifungal activity with increasing doses has been reported for some echinocandins in experimental models of invasive pulmonary aspergillosis (IPA)," investigators in the United States report. "We compared the activity of micafungin and caspofungin administered over a wide dosing range that encompasses clinical exposures (0.25-10 mg/kg) in a neutropenic murine model of IPA. Both echinocandins exhibited dose-dependent reductions in fungal burden; however,...
Source: TB & Outbreaks Week (2008-06-03)
|
